This finding indicated that the inhibition of NLRP3 inflammasome activation may be involved in the beneficial action of salidroside in metabolic disorder, such as NAFLD and type 2 diabetes. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.